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Abstract
In the human larynx, implants a primarily used for the correction of
glottis insufficiency. In a broader sense laryngeal stents may be con-
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sidered as implants as well. Laryngeal implants can be differentiated
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1 Introduction
There is a great variety of devices to be put into the
human larynx for medical reasons. It is a systematic dif-
ference whether only a limited use is intended, like in
laryngeal stents. However, if the device is intended to
remain in the larynx permanently the definition of a
medical implant in the strict sense is fulfilled
2 Laryngeal implants
Surgical procedures aiming at closing a glottic insuffi-
ciency are by far the most important indications for
laryngeal implants. Unilateral lower motor neuron type
paralysis of the recurrent laryngeal nerve is the most
common etiology for this condition. There are two main
groups of products used for these procedures: Implants
in the strict sense, which are made of solid material and
are positioned into the paraglottic space via an open
surgical approach by creating a window in the laryngeal
framework. The idea is to bring the paralyzed vocal cord
into a more median position. In contrastto that there are
substances which are injected into the paralyzed cord in
ordertoincreaseitsvolumeandtoreducetheglottalgap
(injection laryngoplasty). Substances of high viscosity
consisting of particles have been named “injectable im-
plants” since they are serving the same purpose in the
paraglotticspaceassolidimplantsformedialisation.The
following gives an overview for both groups of implants.
2.1 Injectable implants
Probably the best known representative of this group is
Teflon,whichhasbeenthemostcommonlyusedproduct
forinjectionlaryngoplastiesbetween1960and1980[1].
Reports of Teflon particles having migrated to distant or-
gans and repeated observations of severe foreign body
granuloma have made Teflon paste obsolete for the use
in humans [2], [3].
Withtexturedparticlesconsistingofpolydimethylsiloxane
(Vox Implants, until 2001 Bioplastique, producer:
bioplasty bv, Geleen, Niederlande; distributor in Europe:
Medtronic-Xomed, Düsseldorf) quite recently a material
hasbecomeavailablewhichseemstooffercharacteristics
comparable to Teflon while offering an excellent biocom-
patibility. With a mean size of about 200 µm these
particles are not object to phagocytosis and migration,
thus adding to their biological safety. There have been
numerous reports showing a particle size of 65 µm as
limit for lymphatic migration for polydimethylsiloxane
particles [4]. Phagocytosis as key element of cell-medi-
ated immune response like in foreign body reactions is
not possible with particles of that size. For that reason
andduetotheirnon-organicbasicstructurehyperreagib-
ility against polydimethylsiloxane particles have been
observed neither in humans nor in animals [5], [6].
Therefore, anti-allergic testing prior to use is not neces-
sary. Owing to this significant particle size the substance
is of high viscosity, making the use of a high-pressure
administration device mandatory. For the same reason
the needlethrough which the substanceis injected must
be of sufficient gauge. In sharp contrast to resorbable
materials polydimethylsiloxane particles need to be in-
jected far lateral into the paraglottic space in order to
avoid an irregular epithelial lining of the vocal cord sur-
face. This localization is basically equal to external im-
plants used in open thyroplasty. Therefore the term “in-
jectableimplants”hasbeencoinedforpolydimethylsilox-
ane particles (Figure 1). It is not recommended to use
this substance in the awake patient, since accurate pos-
itioning is of crucial importance. The material has been
used in urology and facial plastic surgery for well over 15
years without remarkable substance-associated compli-
cations. In the human larynx several groups using polydi-
methylsiloxane particles have been able to show a per-
manent augmentation effect in the vocal fold leading to
good functionalresultswithout formationof foreign body
granuloma [7], [8], [9], [10], [11], [12]. Overcorrection is
not necessary. In some cases relocation effects may
occur, prior to definitive fixation of particles by sur-
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and can be corrected by an additional injection. Polydi-
methylsiloxane particles have been approved to be used
for injection laryngoplasty in the European Union since
2001.
Figure1:“InjectableImplant”:augmentationintheparaglottic
space
Recently a substance similar to polydimethylsiloxane
particleshasbeenapprovedbyFDAintheUSA,consisting
of hydroxylapatite particles (Radiance FN, Bioform Inc.,
Franksville, Wisconsin/USA). The product is basically
equal to a contrast enhancing substance having been
developed for diagnostic radiology, technique of applica-
tionisidenticaltothatdescribedforpolydimethylsiloxane
particles. Biochemically hydroxilapatite is identical to
bone tissue, its excellent biocompatibility is well known
from many medical applications in different fields. Main
difference to polydimethylsiloxane particles is the poten-
tial resorption in human tissue at a rate which cannot be
calculated. So far there are no data on functional effects
or duration of the augmentation effect. While being offi-
cially approved in the US for use in the human larynx the
product is not yet available on the European market.
2.2 Injectable, resorbable implants
In a broader sense substances may be considered as
laryngeal implants if they are brought into the larynx
withouttheprimary intentionofexplantationatany point
of time, even though they are subject to resorption in
different time ranges depending on their respective bio-
logical characteristics.
Mostpopularrepresentative ofthisgroupis bovinecolla-
gene, being in extensive use in aesthetic facial surgery.
Experience with its use for injection laryngoplasty date
back as far as 1986 [13], [14]. Preparations available
are differing primarily in the concentration of bovine col-
lagen in the solution that comes ready for injection (e.g.
Zyderm1, Zyderm2, Collagen Aesthetics, Palo Alto, USA).
Thereisaspecialpreparationinwhichthecollagenfibers
are cross-linked, supposedly slowing the resorption pro-
cess significantly [14]. The duration of the augmentation
process according to different authors is ranging from
6–18 months. The existence of pre-formed antibodies
against collagene in about 3% of patients makes allergy
testing mandatory prior to use. A testing dosis is injected
subcutaneously into the forearm and is being observed
for 3 weeks. The site of augmentation should be the
laminapropriaoftthevocalfold,becauseanintramuscu-
lar injection would lead to rapid resorption. Due to its low
viscosity low-pressure injection through fine needles is
possible,soapplicationintheawakepatientwithsurface
anesthesiaoftthelarynxisbasicallypossible.Sofarthere
are no reports on substance-associated complications
after injection laryngoplasty using collagene. According
to the manufacturer a specially designed production
process rules out any risk of prion transfer. However,
collagene has still not yet been officially approved for in-
jection laryngoplasty. This off-label use may cause reim-
bursement problems.
Hyaluronic acid has become an alternative to collagene
due to its similar characteristics. This substance is
present in connective tissue in humans and animals and
is already being widely used in aesthetic surgery. Most
products are of avine origin, but synthetically production
is possible, too. Allergic reactions in persons with hyper-
sensitivity against poultry proteins have been described,
but allergic testing prior to use is not mandatory. Pure
hyaluronic acid is resorbed rapidly and is usually embed-
dedinhydrogels(Hylaform,CollagenAestheticsInc.,Palo
Alto, USA) to improve durability [15]. Only few data are
available for vocal fold augmentation [16], [17], [18], the
widespread use as filler in facial aesthetic surgery sug-
gests a durability of 3–6 months. Therefore, hyaluronic
acidseemssuitableprimarilyfornon-permanentinjection
laryngoplasty as in cases of recurrent laryngeal nerve
palsy with electromyographically good prognosis, when
temporary voice improvement is requested to bridge the
time until recovery. For patients hesitating to decide for
definitive thyroplasty or injection laryngoplasty it is often
helpful to experience the possible result using a rapid
resorbable,easy-to-usesubstancewithoutanysignificant
side-effects (“test-drive”).
Formorethan8yearsprocessedcollagenofhumanorigin
hasbeenavailabletocoverskindefectsafterburntrauma
(Alloderm, LifeCell Corporation, Palo Alto, USA). This col-
lagen is being collected from human cadavers having
been tested extensively for potentially transmittable dis-
eases.Themanufacturercooperateswithselectedtissue
banks in North America only to maintain a high level of
safety. So far no case of disease transmission or other
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Aftercollectionthematerialistransportedinanantibiotic
solution,inthefurthercryofractioningprocessallhuman
cells are completely removed with an avital matrix of
dermal collagene and protein remaining. A preparation
of these microparticles is marketed as filler for tissue
defects under the brand name Cymetra. The substance
comes as a powder and needs to be mixed with normal
salineandlidocaineinordertogetaninjectablesolution.
Allergy testing is not necessary; however, patients with
known allergies against antibiotics having been used in
the preparation process must not be treated. Cymetra is
FDA-approved as dermalfiller, but not specificallyfor use
in the human larynx. To date there is only one published
report for injection laryngoplasty [19], showing faster re-
sorptionthanbovinecollagene.Comparativelyfastresorp-
tion, significant higher costs and need to go through a
mixing process prior to use will be shortcomings in Cy-
metra’s competition against other substances.
Bydefinitiontissuefromthesamepatientisnotamedical
implant.Sinceautologousfatisindirectcompetitionwith
the substances discussed earlier it will be mentioned
shortly. Autologous fat has been described as material
for vocal fold augmentation in the early 90ies of the last
century[20].Harvestingisperformedinthesamesession
as augmentation, usually by aspiration or periumbilical
incision. The correct harvesting technique is probably of
major influence on the survival rate of adipocytes after
transplantation[21].Theobviousadvantagesasexcellent
biocompatibility, simple harvesting and minimal costs
made this technique popular worldwide soon. Until the
end of the millennium autologous fat probably has been
themostfrequentlyusedsubstanceforinjectionlaryngo-
plasty. Reports on extent of and time to resorption are
varying. Using MRI long time vitality of the injected fat
tissue could be shown as well as complete resorption
[22], [23]. This lack of reproducibility and the advent of
numerous alternative materials lead to a continuing de-
crease of autologous fat transplantation [24].
2.3 Solid implantats
Systematic developmentof surgicalvocal fold medialisa-
tion as well as the term thyroplasty goes back to Isshiki
[25]. He described the technique of forming a wedge by
cutting a window into the laryngeal framework at the
glotticlevel which was securedinto the paraglotticspace
by a custom-made silastic implant. Due to irreproducible
resorption of the impressed cartilage Sasaki’s [26]
modification became popular, which removed the cartil-
agewithinthewindowcompletelywiththesilasticimplant
doing the complete medialisation effect. Biological com-
patibilityofcompletelypolymerizedmedicalgradesilicone
is excellent; extrusion rate seems not to be different to
other medical implants [27]. Good compatibility in com-
binationwithlowmaterialcostsandpossibilityofcustom-
ization have made thyroplasty using silastic implants ex-
tremely popular for a long time in the US [28]. On the
other hand the time-consuming non-standardized and
hardly reproducible preparation of the implant at the op-
eration table has fueled the development of pre-formed
devices.TheVoComsystemconsistsofexcellentbiocom-
patible hydroxylapatite and comes with 5 implant sizes
and 4 baseplates offering a wide range of possible com-
binations [29]. Due to its tendency to osseointegrate
hydroxylapatite is almost impossible to remove after im-
plantation.TheMontgomerysystem[30]issiliconebased
and comes with 5 different sizes for males and females,
respectively. Dedicated tools are necessary for the im-
plantation process, making the system quite expansive.
In contrast to that the Titanium Vocal Fold Medialization
Implant (TVFMI) can be inserted using standard equip-
ment (Figure 2) and comes in 3 sizes differing in length
only [31]. Ease of use and comparatively low cost has
made the TVFMI popular all over Europe. Functional re-
sults seem to equal regardless of type of implant.
Figure 2: Titanium Vocal Fold Medialization Implant
3 Laryngeal stents
Indications for stents in the human larynx are postopera-
tivestabilizationafterlaryngofissure(asinlaryngotracheal
reconstruction for repair of laryngotracheal stenosis),
stenting of a traumatized larynx to prevent formation of
synechia and stenosis as well as preservation or recon-
struction of a sharp-angled anterior commissure after
oncological resection in this area. Long-term stenting for
progressive dilatation of laryngotracheal stenosis is con-
sidered obsolete nowadays and will not be discussed.
The Montgomery T-Tube has been introduced as early as
1965 [32] and has remained the laryngeal stent most
widely used (Figure 3). It is a T-shaped uncuffed silicone
tube with two long legs to be put into the tracheaand the
subglottic larynx while the short leg is positioned in the
tracheostomy site (Figure 4). This tracheostomal leg is to
be unplugged only for cleaning and in emergency. Pro-
longed breathing through this outer part of the T-tube in-
evitably leads to formation of crusts blocking the airway
within relatively short time. For adults there are sizes
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entlength.Therearepaediatricvariations(withtheouter
leg angled differently) coming with outer diameters ran-
ging from 4.5 to 8 mm and a great variety of different
lengths.
Figure 3: Montgomery T-Tube
Figure 4: Montgomery T-Tube, schematic drawing of correct
positioning
The Montgomery T-tube has replaced almost completely
other types of laryngeal stents like those by Albouker or
Berkovits [33], which will not be described here. Signific-
ant disadvantages of the Montgomery T-tube are the
tendency to stimulate granulation tissue at the cranial
and caudal end, laceration of the subglottic aspects of
the vocal fold if positioned close to the glottic level and
aspiration if positioned transglottic. There is also no
standard connector to respirators [34]. Primarily in the
narrow paediatric types crust formation may lead to dra-
maticsituationsrapidly.AmodificationbySchultz-Coulon
named“double-cannula-technique”[35]helpseffectively
to avoid this: The external leg of the T-tube is being split
in a sagittal plane allowing for the introduction of a
standard tracheal cannula without discomfort for the
patient.Thecranialendisnolongerrequiredasanairway
and can be sutured to prevent aspiration.
AfterlaryngotrachealreconstructionaMontgomeryT-tube
is typical left in place for about 3 weeks, but in case of
multiple laryngofissure requiring long term stenting this
can be much longer [36]. There is broad agreement
among all relevant authors that long term use of a
Montgomery T-tube should be a rare exception for cases
inwhichreconstructionofthecompromisedairwayisnot
feasible.
AlthoughtheMontgomeryT-tubehasbeenusedsuccess-
fully for decades the problems mentioned should not be
underestimated.WiththeLT-moldapromisingnewdevice
is on the way (but not yet commercially available) appar-
ently avoiding some of the complications experienced
with the T-tube in the paediatric population [37].
Laser resections in the anterior commissure may lead to
formation of synechia, which also may occur after re-
peatedremovalofbenignlesions(i.e.papilloma)orpartial
laryngectomy via open approach. Classically surgical
treatment consists of open laryngofissure, synechia div-
ision and keel implantation for about 3 weeks [38]. Im-
plantation and ex-plantation requiring an open approach
andusuallytracheostomyistime-consuminganduncom-
fortable for the patient. Transoral endoscopic synechia
division(usuallywith the CO2-laser)andstentapplication
to avoid resynechia has become increasingly popular for
these conditions after the introduction of the endo-
extralaryngealneedledriver[39].Theseendoscopicstents
canbemadeofsiliconeorPDSfoilsorsilasticblocksand
need to be custom made at the operating table.
TheMontgomerylarynxstentisformedaftermoldsofthe
endolarynx and is made of radio-opaque silicone [38]. It
comes in 4 different sizes and maybe used for postop-
erative or posttraumatic stenting and for fixation of mu-
cosatransplants.Thisstentissecuredwithtranslaryngeal
sutures, which can be problematic. The use of this stent
nowadays is primarily in extended laryngeal trauma with
significant mucosa laceration in order to provide simul-
taneouslystabilizationofthelaryngealframeworkaswell
as prophylaxis against synechia formation [40].
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